QVT Financial LP 4

What Happened
QVT Financial LP (reported as "Director by Deputization") sold a total of 1,438,163 common shares of Roivant Sciences Ltd. (ROIV) in multiple open-market transactions between June 26 and June 30, 2026, for aggregate proceeds of approximately $49.35 million. Individual trades: 300,783 shares @ $33.92 (≈ $10,202,559) and 325,000 @ $34.07 (≈ $11,072,750) on 2026-06-26; 200,000 @ $34.44 (≈ $6,888,000) and 600,000 @ $34.59 (≈ $20,754,000) on 2026-06-29; and 12,380 @ $35.28 (≈ $436,766) on 2026-06-30. These were sales (not purchases or exercises).

Key Details

• Dates & prices: 2026-06-26 (300,783 @ $33.92; 325,000 @ $34.07), 2026-06-29 (200,000 @ $34.44; 600,000 @ $34.59), 2026-06-30 (12,380 @ $35.28).
• Total sold: 1,438,163 shares for ~$49,354,075.
• Shares owned after transactions: QVT (via affiliated entities) may be deemed to beneficially own 23,723,074 common shares (per filing footnote).
• Footnotes: F1 clarifies the post-transaction aggregate beneficial ownership figure applies to QVT and its GP; F2 states QVT provides advisory services to affiliated entities and disclaims beneficial ownership except to the extent of any pecuniary interest.
• Filing: Form 4 filed 2026-06-30 reporting transactions from 2026-06-26 onward; no late-filing indication in the report.

Context
This filing reflects institutional selling by an investment manager/affiliate group rather than a straightforward executive buy or sell by an individual CEO/CFO. The filing’s footnotes indicate ownership is held through affiliated entities and that QVT disclaims full beneficial ownership except for pecuniary interest—useful to know when assessing how these sales affect insider alignment with shareholders. The report is factual and does not state motives; sales by investment firms can be for portfolio management or liquidity rather than a signal about the company’s outlook.